Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$119.53 USD
+1.75 (1.49%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $119.56 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BPMC 119.53 +1.75(1.49%)
Will BPMC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BPMC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BPMC
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?
BPMC: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
Other News for BPMC
Expert Ratings For Blueprint Medicines
Blueprint Medicines: A Strong Buy on Robust Pipeline and Strategic Growth Opportunities
Blueprint Medicines management to meet with JMP Securities
Blueprint Medicines management to meet with JMP Securities
Blueprint Medicines management to meet with JMP Securities